Low-dose depot medication in schizophrenia

Peter L. Burnett, Cherrie A. Galletly, Robert J. Moyle, C. Richard Clark

    Research output: Contribution to journalArticlepeer-review

    14 Citations (Scopus)

    Abstract

    Depot antipsychotic medication is a major component of the maintenance treatment of schizophrenia, but it is still not clear what constitutes an appropriate dose. A number of studies comparing low with standard doses of depot antipsychotic medication on a variety of outcome meas ures have been published in the last decade. A review of these studies indicates that, compared to standard-dose treatment, low- dose medication tends to improve psychosocial function and reduce the frequency of side effects but may result in an in crease in positive symptoms. In such cases, a temporary increase in dose appears to control symptoms and terminate relapse episodes. An explanation of the relative efficacy of low-dose treatment may be derived from recent work in radioreceptor ligand binding.

    Original languageEnglish
    Pages (from-to)155-164
    Number of pages10
    JournalSchizophrenia bulletin
    Volume19
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 1993

    Fingerprint

    Dive into the research topics of 'Low-dose depot medication in schizophrenia'. Together they form a unique fingerprint.

    Cite this